LBP Polysaccharides

Compound Class	Lycium barbarum polysaccharides (LBP) — a heterogeneous family of glycoconjugates, principally arabinogalactan-protein complexes
Composition	Arabinose, galactose, glucose, rhamnose, mannose, xylose and uronic acids, covalently linked to a polypeptide backbone
Botanical Source	Lycium barbarum (goji berry; wolfberry; gou qi zi)
Plant Part(s)	Fruit
Typical Standardisation	LBP by phenol-sulfuric or gravimetric method; 40–50% commercial range
Primary Applications	Antioxidant and neuroprotective positioning; ocular and hepatic research; prebiotic activity
Claim Strength (Overview)	Emerging — extensive preclinical literature, but well-designed human RCTs are scarce and underpowered
Buy from Herbuno	LBP Polysaccharides 50% Powder (Goji Extract) | Standardized Lycium barbarum → LBP Polysaccharides 40% Powder (Goji Extract) | Standardized Lycium barbarum →

Name origin: LBP is simply an abbreviation of Lycium barbarum polysaccharides, and the abbreviation itself signals the compositional vagueness that defines this ingredient: it names a source organism and a chemical class, not a molecule or even a well-defined mixture. The Chinese name gou qi zi and the marketing name "goji" refer to the same fruit; "wolfberry" is a further synonym. Traditional use: Lycium barbarum fruit appears in Chinese materia medica from the Shennong Ben Cao Jing onward as a liver- and kidney-tonifying and eye-brightening herb — the ophthalmic indication being notably specific and persistent across two millennia of use, and the one that modern retinal research has most directly pursued. It is consumed as a food as much as a medicine, typically dried and eaten whole or infused. Research trajectory: LBP research expanded dramatically alongside the "superfruit" commercialisation of goji in the 2000s, generating a large volume of in-vitro and rodent literature reporting antioxidant, neuroprotective, hepatoprotective, and immunomodulatory activity. The honest assessment, which this page makes explicitly, is that the human clinical literature has not kept pace: the systematic reviews are candid that well-designed randomized trials remain scarce and underpowered. Commercial source: Lycium barbarum fruit extract standardized to LBP content; note that this assay shares all the specificity problems documented on the Polysaccharides page in this index.

---

Evidence for LBP Polysaccharides Applications

The evidence position must be stated candidly rather than curated. A systematic review of the potential therapeutic use of Lycium barbarum polysaccharides examined twenty selected papers, of which only two were randomized controlled trials (one double-blinded, one double-blinded placebo-controlled), the remainder being in-vivo, in-vitro, and chemical studies; the authors found good evidence from existing studies for antifibrotic, antioxidising, neuroprotective, anticancer, and anti-inflammatory effects, while explicitly concluding that there is a need for large-scale clinical trials to support its use in humans (Tian 2019). Two RCTs out of twenty papers is the number a formulator needs to hold in mind when reading the enthusiastic preclinical literature. Claim strength: Emerging.

The same review is unusually direct about the limitations, and its candour deserves quoting in substance. It records an evident lack of well-designed randomized controlled trials evaluating LBP in humans; notes that although RCTs exist for diabetes and diabetic retinopathy, their sample sizes are insufficient for the results to have significant impact on clinical management; and identifies a major limitation of current research as the lack of standardization and quality control for the LBP used across studies (Tian 2019). That last point is the crux: if the LBP used in study A is not the same material as in study B, the literature cannot accumulate. Claim strength: Emerging.

What positive human data exists is modest and worth reporting accurately rather than inflating. A double-blinded, placebo-controlled RCT in 67 patients with type 2 diabetes compared 300 mg/day oral LBP against controls and found, at three months, a significant increase in HDL from baseline relative to controls. A significant HDL increase in a 67-patient trial is a real but narrow finding, and it is a considerable distance from the sweeping antioxidant and longevity claims that accompany goji commercially. Registered trials in depression and subthreshold depression have also used 300 mg/day over six weeks. Claim strength: Emerging.

An application with a more coherent mechanistic story is prebiotic activity. LBP has been characterised as a prebiotic candidate promoting proliferation of Bifidobacterium and Lactobacillus strains, with monosaccharide composition characterised by gas chromatography. This is a mechanistically plausible and testable application that does not require systemic absorption of a high-molecular-weight polymer — which is, frankly, the least defensible assumption underlying many LBP claims, since large polysaccharides are not meaningfully absorbed intact. Claim strength: Emerging.

The compositional heterogeneity is the structural problem underlying everything above. "LBP" is not one substance but a family of arabinogalactan-protein glycoconjugates whose monosaccharide ratios, molecular weight distribution, and protein content vary with cultivar, growing region, harvest, and — critically — extraction method. Since structure determines function in polysaccharide pharmacology, and since no consensus structural specification exists, two products both labelled "LBP 50%" may be materially different materials. Until a structural standard is agreed, claims for this ingredient should remain conservative. Claim strength: High (compositional fact).

---

Dosage & Formulator Specification

Herbuno carries Lycium barbarum fruit extract standardized to 50% and 40% LBP, alongside goji berry extract powder and water-soluble and oil-soluble goji extracts. The general Polysaccharides page in this index documents the class-level standardisation problems that apply here with full force, and buyers are directed to it before specifying on an LBP percentage alone.

Human trial dosing, such as it is, has centred on 300 mg/day of LBP — the dose used in the type 2 diabetes RCT and in registered depression trials over six weeks. Formulators should note the modesty of that figure relative to typical commercial goji supplement servings, and should be candid that it rests on a very thin human evidence base. Given that high-molecular-weight polysaccharides are not absorbed intact, formulators positioning LBP on systemic antioxidant grounds are making an assumption the pharmacokinetics do not readily support, and a gut-local or prebiotic framing is the more defensible one.

Analytical verification should not stop at an LBP percentage by phenol-sulfuric assay, which measures total carbohydrate and is inflatable with free sugars — a particular concern for a fruit-derived material naturally high in simple sugars. Request the monosaccharide composition profile, molecular-weight distribution, and protein content, since LBP is a glycoconjugate rather than a pure polysaccharide. Free-sugar content should be quantified separately and subtracted. Heavy-metal and pesticide testing warrants attention given goji’s intensive cultivation in some sourcing regions.

Lycium barbarum has a long history of dietary consumption and is generally well tolerated; the systematic review noted a lack of demonstrated toxic effects, including to corneal epithelial cells in topical ocular contexts. Two cautions warrant statement. Goji has been reported in case literature to potentiate warfarin, with elevated INR, and concurrent use with anticoagulants therefore warrants caution and medical supervision. Second, given the immunomodulatory activity reported preclinically, standard caution is appropriate for individuals on immunosuppressive therapy. Allergic reactions to goji have been reported, including in individuals with sensitivity to other Solanaceae.

---

Frequently Asked Questions — LBP Polysaccharides

How strong is the human evidence for LBP?
Thin, and the systematic reviews say so plainly. One review of twenty papers found only two were randomized controlled trials — the rest were in vitro, in vivo, or chemical studies. The authors explicitly called for large-scale clinical trials and noted that existing RCTs in diabetes and retinopathy are too small to affect clinical management.

What did the positive LBP trial actually find?
A double-blinded placebo-controlled RCT in 67 type 2 diabetes patients found that 300 mg/day LBP produced a significant increase in HDL from baseline at three months. That is a real but narrow finding, and a considerable distance from the sweeping antioxidant and longevity claims that accompany goji commercially.

Is LBP absorbed into the bloodstream?
High-molecular-weight polysaccharides are not meaningfully absorbed intact, which makes systemic antioxidant claims for LBP an assumption the pharmacokinetics do not readily support. A gut-local or prebiotic framing is more defensible — LBP has been characterised as promoting Bifidobacterium and Lactobacillus proliferation.

Why is LBP standardisation a problem?
Because "LBP" names a source and a chemical class, not a defined substance. It is a family of arabinogalactan-protein glycoconjugates whose composition varies with cultivar, region, harvest, and extraction method. Researchers have identified this lack of standardisation as a major limitation — if the LBP in one study is not the same material as in another, the literature cannot accumulate.

Related compounds: Polysaccharides, Zeaxanthin, Beta-Glucans, Lutein

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery